Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders

Genome Medicine

Volumn 2, Issue 3, 2010, Pages

  Pendyala, Gurudutt ^a   Fox, Howard S ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; PROSTAGLANDIN SYNTHASE; SUPEROXIDE DISMUTASE;

CELL ORGANELLE; CEREBROSPINAL FLUID; HIV ASSOCIATED DEMENTIA; HUMAN; METABOLOMICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

EID: 78751697840     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm143     Document Type: Review

References (81)

1. Ong EL. Common AIDS-associated opportunistic infections. Clin Med 2008, 8:539-543.
2. Yadav A, Collman RG. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol 2009, 4:430-447. 10.1007/s11481-009-9174-2, 19768553.
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799. 10.1212/01.WNL.0000287431.88658.8b, 17914061.
4. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 2009, 19:169-185. 10.1007/s11065-009-9092-3, 19424802.
5. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003, 17:1539-1545. 10.1097/00002030-200307040-00015, 12824792.
6. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002, 8:136-142. 10.1080/13550280290049615, 11935465.
7. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009, 19:152-168. 10.1007/s11065-009-9102-5, 2690857, 19462243.
8. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008, 20:33-47. 10.1080/09540260701877894, 18240061.
9. Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, Moore D, Ellis R, Cherner M, Gelman B, Morgello S, Singer E, Grant I, Masliah E. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009, 15:360-370. 10.3109/13550280903131915, 20175693.
10. Achmat Z, Simcock J. Combining prevention, treatment and care: lessons from South Africa. AIDS 2007, 21(Suppl 4):S11-S20. 10.1097/01.aids.0000279702.71062.52, 17620746.
11. Aracena-Genao B, Navarro JO, Lamadrid-Figueroa H, Forsythe S, Trejo-Valdivia B. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico. AIDS 2008, 22(Suppl 1):S141-S148. 10.1097/01.aids.0000327635.74919.fd, 18664946.
12. Battegay M, Elzi L. Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities. Swiss Med Wkly 2009, 139:564-570.
13. Blankson JN. Viral reservoirs and HIV-specific immunity. Curr Opin HIV AIDS 2006, 1:147-151.
14. Kiertiburanakul S, Sungkanuparph S. Emerging of HIV drug resistance: epidemiology, diagnosis, treatment and prevention. Curr HIV Res 2009, 7:273-278. 10.2174/157016209788347976, 19442122.
15. Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy 21:4-9. 10.1016/j.drugpo.2009.08.003, 19747811.
16. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006, 1:280-295. 10.1007/s11481-006-9023-5, 18040805.
17. Cohen GM. Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries. AIDS 2007, 21(Suppl 4):S81-S87. 10.1097/01.aids.0000279710.47298.5c, 17620757.
18. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE. A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 2009, 64:133-145. 10.1016/j.neuron.2009.09.042, 19840555.
19. Kraft-Terry SD, Stothert AR, Buch S, Gendelman HE. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis 2010, 37:542-548. 10.1016/j.nbd.2009.12.015, 20044002.
20. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992, 42:1736-1739.
21. Gendelman HE, Lipton SA, Tardieu M, Bukrinsky MI, Nottet HS. The neuropathogenesis of HIV-1 infection. J Leukoc Biol 1994, 56:389-398.
22. Gray F, Hurtrel M, Hurtrel B. Early central nervous system changes in human immunodeficiency virus (HIV)-infection. Neuropathol Appl Neurobiol 1993, 19:3-9. 10.1111/j.1365-2990.1993.tb00399.x, 8474597.
23. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001, 410:988-994. 10.1038/35073667, 11309629.
24. Diesing TS, Swindells S, Gelbard H, Gendelman HE. HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read 2002, 12:358-368.
25. Gartner S. HIV infection and dementia. Science 2000, 287:602-604. 10.1126/science.287.5453.602, 10691542.
26. Lane TE, Buchmeier MJ, Watry DD, Fox HS. Expression of inflammatory cytokines and inducible nitric oxide synthase in brains of SIV-infected rhesus monkeys: applications to HIV- induced central nervous system disease. Mol Med 1996, 2:27-37. 2230039, 8900532.
27. Nuovo GJ, Alfieri ML. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. Mol Med 1996, 2:358-366. 10.1007/s0089460020358, 2230156, 8784788.
28. Sharer LR. Pathology of HIV-1 infection of the central nervous system. A review. J Neuropathol Exp Neurol 1992, 51:3-11. 10.1097/00005072-199201000-00002, 1740672.
29. Marcondes MC, Burudi EM, Huitron-Resendiz S, Sanchez-Alavez M, Watry D, Zandonatti M, Henriksen SJ, Fox HS. Highly activated CD8(+) T cells in the brain correlate with early central nervous system dysfunction in simian immunodeficiency virus infection. J Immunol 2001, 167:5429-5438.
30. Roberts ES, Huitron-Resendiz S, Taffe MA, Marcondes MC, Flynn CT, Lanigan CM, Hammond JA, Head SR, Henriksen SJ, Fox HS. Host response and dysfunction in the CNS during chronic simian immunodeficiency virus infection. J Neurosci 2006, 26:4577-4585. 10.1523/JNEUROSCI.4504-05.2006, 16641237.
31. Burudi EM, Fox HS. Simian immunodeficiency virus model of HIV-induced central nervous system dysfunction. Adv Virus Res 2001, 56:435-468. 10.1016/S0065-3527(01)56035-2, 11450309.
32. Fox HS. Virus-host interaction in the simian immunodeficiency virus-infected brain. J Neurovirol 2008, 14:286-291. 10.1080/13550280802132824, 2665180, 18780229.
33. Fox HS, Gold LH, Henriksen SJ, Bloom FE. Simian immunodeficiency virus: a model for neuroAIDS. Neurobiol Dis 1997, 4:265-274. 10.1006/nbdi.1997.0159, 9361303.
34. Rausch DM, Murray EA, Eiden LE. The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases. J Leukoc Biol 1999, 65:466-474.
35. Sharer LR, Baskin GB, Cho ES, Murphey-Corb M, Blumberg BM, Epstein LG. Comparison of simian immunodeficiency virus and human immunodeficiency virus encephalitides in the immature host. Ann Neurol 1988, 23(Suppl):S108-S112. 10.1002/ana.410230727, 2831797.
36. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003, 2:566-580. 10.1038/nrd1130, 12838269.
37. Horning EC, Horning MG. Metabolic profiles: gas-phase methods for analysis of metabolites. Clin Chem 1971, 17:802-809.
38. Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, Waldemar G, Minthon L, Blennow K. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 2007, 64:366-370. 10.1001/archneur.64.3.366, 17353378.
39. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 2008, 29:961-968. 10.1016/j.neurobiolaging.2007.01.011, 17321007.
40. Thompson EJ. Cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1995, 59:349-357. 10.1136/jnnp.59.4.349, 486067, 7561910.
41. Kanekiyo T, Ban T, Aritake K, Huang ZL, Qu WM, Okazaki I, Mohri I, Murayama S, Ozono K, Taniike M, Goto Y, Urade Y. Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. Proc Natl Acad Sci USA 2007, 104:6412-6417. 10.1073/pnas.0701585104, 1851035, 17404210.
42. Thouvenot E, Urbach S, Dantec C, Poncet J, Seveno M, Demettre E, Jouin P, Touchon J, Bockaert J, Marin P. Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid. J Proteome Res 2008, 7:4409-4421. 10.1021/pr8003858, 18774838.
43. Pan S, Zhu D, Quinn JF, Peskind ER, Montine TJ, Lin B, Goodlett DR, Taylor G, Eng J, Zhang J. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 2007, 7:469-473. 10.1002/pmic.200600756, 17211832.
44. Rozek W, Ricardo-Dukelow M, Holloway S, Gendelman HE, Wojna V, Melendez LM, Ciborowski P. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res 2007, 6:4189-4199. 10.1021/pr070220c, 17929958.
45. Pendyala G, Trauger SA, Kalisiak E, Ellis RJ, Siuzdak G, Fox HS. Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys. J Proteome Res 2009, 8:2253-2260. 10.1021/pr800854t, 19281240.
46. Speth C, Williams K, Hagleitner M, Westmoreland S, Rambach G, Mohsenipour I, Schmitz J, Wurzner R, Lass-Florl C, Stoiber H, Dierich MP, Maier H. Complement synthesis and activation in the brain of SIV-infected monkeys. J Neuroimmunol 2004, 151:45-54. 10.1016/j.jneuroim.2004.02.013, 15145603.
47. Morgan BP, Gasque P, Singhrao S, Piddlesden SJ. The role of complement in disorders of the nervous system. Immunopharmacology 1997, 38:43-50. 10.1016/S0162-3109(97)00059-3, 9476113.
48. Nolte C, Moller T, Walter T, Kettenmann H. Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience 1996, 73:1091-1107. 10.1016/0306-4522(96)00106-6, 8809827.
49. Osaka H, Mukherjee P, Aisen PS, Pasinetti GM. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 1999, 73:303-311. 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2, 10321830.
50. Boos L, Szalai AJ, Barnum SR. C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci Lett 2005, 387:68-71. 10.1016/j.neulet.2005.07.015, 16085360.
51. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol 1989, 56:259-262. 10.1007/BF02890024, 2565620.
52. Veerhuis R, Janssen I, Hack CE, Eikelenboom P. Early complement components in Alzheimer's disease brains. Acta Neuropathol 1996, 91:53-60. 10.1007/s004019570001, 8773146.
53. Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 1999, 154:927-936. 1866427, 10079271.
54. Gasque P, Neal JW, Singhrao SK, McGreal EP, Dean YD, Van BJ, Morgan BP. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol Neurobiol 2002, 25:1-17. 10.1385/MN:25:1:001, 11890454.
55. Laspiur JP, Anderson ER, Ciborowski P, Wojna V, Rozek W, Duan F, Mayo R, Rodriguez E, Plaud-Valentin M, Rodriguez-Orengo J, Gendelman HE, Melendez LM. CSF proteomic fingerprints for HIV-associated cognitive impairment. J Neuroimmunol 2007, 192:157-170. 10.1016/j.jneuroim.2007.08.004, 2248223, 17950469.
56. Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, Medina-Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, Mellors JW, Bowser R, Wiley CA. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008, 173:130-143. 10.2353/ajpath.2008.080045, 2438291, 18556781.
57. Roberts ES, Zandonatti MA, Watry DD, Madden LJ, Henriksen SJ, Taffe MA, Fox HS. Induction of pathogenic sets of genes in macrophages and neurons in neuroAIDS. Am J Pathol 2003, 162:2041-2057. 1868118, 12759259.
58. Li W, Malpica-Llanos TM, Gundry R, Cotter RJ, Sacktor N, McArthur J, Nath A. Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology 2008, 70:1753-1762. 10.1212/01.wnl.0000282761.19578.35, 18077799.
59. Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol 1994, 35:592-597. 10.1002/ana.410350513, 7910004.
60. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169. 10.1074/mcp.M400129-MCP200, 15385600.
61. Lichenstein HS, Lyons DE, Wurfel MM, Johnson DA, McGinley MD, Leidli JC, Trollinger DB, Mayer JP, Wright SD, Zukowski MM. Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family. J Biol Chem 1994, 269:18149-18154.
62. Pendyala G, Trauger SA, Siuzdak G, Fox HS. Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease. J Proteome Res 9:352-358. 10.1021/pr900685u, 19908921.
63. Rozek W, Horning J, Anderson J, Ciborowski P. Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment. Proteomics Clin Appl 2008, 2:1498-1507.
64. Jerkovic L, Voegele AF, Chwatal S, Kronenberg F, Radcliffe CM, Wormald MR, Lobentanz EM, Ezeh B, Eller P, Dejori N, Dieplinger B, Lottspeich F, Sattler W, Uhr M, Mechtler K, Dwek RA, Rudd PM, Baier G, Dieplinger H. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J Proteome Res 2005, 4:889-899. 10.1021/pr0500105, 15952736.
65. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2001, 276:46024-46030. 10.1074/jbc.M105132200, 11590166.
66. Burdo TH, Wood MR, Fox HS. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol 2007, 81:1504-1511. 10.1189/jlb.1106711, 2490714, 17369493.
67. Burdo TH, Ellis RJ, Fox HS. Osteopontin is increased in HIV-associated dementia. J Infect Dis 2008, 198:715-722. 10.1086/590504, 2587027, 18616394.
68. Marcondes MC, Lanigan CM, Burdo TH, Watry DD, Fox HS. Increased expression of monocyte CD44v6 correlates with the development of encephalitis in rhesus macaques infected with simian immunodeficiency virus. J Infect Dis 2008, 197:1567-1576. 10.1086/588002, 2494986, 18471064.
69. Gelman BB, Nguyen TP. Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. J Neuroimmune Pharmacol 2010, 5:92-102. 10.1007/s11481-009-9168-0, 2824116, 19693676.
70. Evergren E, Benfenati F, Shupliakov O. The synapsin cycle: a view from the synaptic endocytic zone. J Neurosci Res 2007, 85:2648-2656. 10.1002/jnr.21176, 17455288.
71. Miller RF, Green AJ, Giovannoni G, Thompson EJ. Detection of 14-3-3 brain protein in cerebrospinal fluid of HIV infected patients. Sex Transm Infect 2000, 76:408. 10.1136/sti.76.5.408, 1744200, 11141866.
72. Wakabayashi H, Yano M, Tachikawa N, Oka S, Maeda M, Kido H. Increased concentrations of 14-3-3 epsilon, gamma and zeta isoforms in cerebrospinal fluid of AIDS patients with neuronal destruction. Clin Chim Acta 2001, 312:97-105. 10.1016/S0009-8981(01)00595-2, 11580914.
73. Helke KL, Queen SE, Tarwater PM, Turchan-Cholewo J, Nath A, Zink MC, Irani DN, Mankowski JL. 14-3-3 protein in CSF: an early predictor of SIV CNS disease. J Neuropathol Exp Neurol 2005, 64:202-208.
74. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Ann Neurol 1997, 42:963-972. 10.1002/ana.410420618, 9403489.
75. Nordstrom A, Lewensohn R. Metabolomics: moving to the clinic. J Neuroimmune Pharmacol 2010, 5:4-17. 10.1007/s11481-009-9156-4, 19399626.
76. Pendyala G, Want EJ, Webb W, Siuzdak G, Fox HS. Biomarkers for neuroAIDS: the widening scope of metabolomics. J Neuroimmune Pharmacol 2007, 2:72-80. 10.1007/s11481-006-9041-3, 18040828.
77. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, Mouradian MM, Sadler AE, Keilp J. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991, 29:202-209. 10.1002/ana.410290215, 1826418.
78. Heyes MP, Jordan EK, Lee K, Saito K, Frank JA, Snoy PJ, Markey SP, Gravell M. Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid. Brain Res 1992, 570:237-250. 10.1016/0006-8993(92)90587-Y, 1535532.
79. Giovannoni G, Miller RF, Heales SJ, Land JM, Harrison MJ, Thompson EJ. Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction. J Neurol Sci 1998, 156:53-58. 10.1016/S0022-510X(98)00021-5, 9559987.
80. Svenningsson A, Petersson AS, Andersen O, Hansson GK. Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. Neurology 1999, 53:1880-1882.
81. Wikoff WR, Pendyala G, Siuzdak G, Fox HS. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest 2008, 118:2661-2669. 10.1172/JCI34138, 2398736, 18521184.